Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis

Clinical Chemistry

Volumn 54, Issue 1, 2008, Pages 188-196

  Garnero, Patrick ^a,b   Vergnaud, Philippe ^a   Hoyle, Nicholas ^c  

^a INSERM   (France)

^b Synarc   (France)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CALCIUM; PARATHYROID HORMONE; VITAMIN D;

ADULT; AMINO TERMINAL SEQUENCE; ARTICLE; ASSAY; AWARENESS; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MALE; MEDICAL RESEARCH; METHODOLOGY; MONOTHERAPY; OSSIFICATION; POSTMENOPAUSE OSTEOPOROSIS; PREMENOPAUSE; PROTEOMICS; RANDOMIZATION; SAMPLE; SERUM; STATISTICAL SIGNIFICANCE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TEMPERATURE;

ADULT; AGED; ALENDRONATE; AUTOANALYSIS; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; FASTING; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; PROCOLLAGEN; SERUM;

EID: 38749150609     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2007.094953     Document Type: Article

References (34)

1. Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 2006;119:S25-31.
2. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
3. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349:1216-26.
4. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15.
5. Garnero P, Grimaux M, Seguin P, Delmas PD. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 1994;9:255-4.
6. Ivaska KK, Hentunen TA, Vaaraniemi J, Ylipahkala H, Pettersson K, Vaananen HK. Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro. J Biol Chem 2004;279:18361-9.
7. Delmas PD, Demiaux B, Malaval L, Chapuy MC, Meunier PJ. Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone. Calcif Tissue Int 1986;38:60-1.
8. Price A, Williamson MK, Lothringer LW. Origin of vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem 1981;256:12760-6.
9. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993;77:1046-53.
10. Gomez B, Ardakanis S, Ju J, Jenkins D, Cerelli MJ, Daniloff GY, Kung VT. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase in serum. Clin Chem 1995;41:1560-6.
11. Risteli J, Risteli L. Products of bone collagen metabolism. In: Dynamics of bone and cartilage metabolism (MJ Seibel, SP Robins, JP Bilezikian, eds). Academic Press, San Diego, 1999; pp: 275-87.
12. Brandt J, Krogh T, Jensen CH, Frederiksen JK, Teisner B. Thermal instability of the trimeric structure of the N-terminal propeptide of human procollagen type I in relation to assay technology. Clin Chem 1999;45:47-53.
13. Linkhart SG, Linkhart TA, Taylor AK, Wergedal JE, Bettica P, Baylink DJ. Synthetic peptide-based immunoassay for amino-terminal propeptide of type I procollagen: application for evaluation of bone formation. Clin Chem 1993;39:2254-8.
14. Ebeling PR, Peterson JM, Riggs BL. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res 1992;7:1243-50.
15. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 1996;42:947-54.
16. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005;20:962-70.
17. Hannon RA, Bluhmson A, Naylor KE, Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy. J Bone Miner Res 1998;13:1124-33.
18. Garnero P, Delmas PD. Variability and response of urinary resorption markers to hormone replacement therapy. J Bone Miner Res 1999;14:470-1.
19. Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 2002;30:886-90.
20. Garnero P, Borel O, Delmas PD. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 2001;47:694-702.
21. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
22. Lomeo A, Bolner A. Stability of several biochemical markers of bone metabolism. Clin Chem 2000;46:1200-1.
23. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996;11:827-34.
24. Chiu KM, Ju J, Mayes D, Bacchetti P, Weitz S, Arnaud CD. Changes in bone resorption during the menstrual cycle. J Bone Miner Res 1999;14:609-15.
25. Glover SJ, Rogers A, Finigan J, Garnero P, Eastell R. Establishing a reference range for bone turnover in young, healthy women. J Bone Miner Res 2006;(suppl 1):S233.
26. Garnero P, Sornay-Rendu E, Claustrat B, Delmas P. Biochemical markers of bone turnover, endogeneous hormones and the risk of fractures in postmenopausal women: the Ofely study. J Bone Miner Res 2000;15:1526-36.
27. Szulc P, Garnero P, Munoz F, Marchand F, Delmas PD. Cross-sectional evaluation of bone metabolism in men. J Bone Miner Res 2001;16:1642-50.
28. Fatayerji D, Eastell R. Age-related changes in bone turnover in men. J Bone Miner Res 1997;1 4:1203-10.
29. Delmas PD, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 2004;34:599-604.
30. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 2006;21:1785-90.
31. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004;19:1250-8.
32. Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, et al. Reduction in P1NP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 2004;34:344-51.
33. Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2006;91:1370-5.
34. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Eval Clin Lab Sci 1989;27:409-39.